patents
We, POSVAX, has the vision to become a global
bio-pharmaceutical company by challenging vaccines
and anticancer drugs industries.
-
Cell culture technology
-
High efiicacy purification
system for vaccine antigen
-
Registration
-
Apply
Cell Culture
Technology
High Efficacy Purification
System for Vaccine Antigen
Methods of enhancing HPV L1 protein production yield
Registered Patents(* marked)
- *Rep. Korea: 10-1458270 (2014. 10. 29)
- *U.S.A.: 8,871,466 (2014. 10. 28)
- *Europe: 12801099.8 (2014. 01. 06)
- *Australia: 2012270418 (2015. 11. 26)
- *Canada: 2,839,427 (2016. 09. 27)
- *Japan: 6001064 (2016. 09. 09)
- *Indonesia: 314654 (2019. 06. 25)
- *China: ZL2012280029590.X (2016. 04. 13)
- *Brazil: BR 11 2013 031338-8 (2021. 04. 20)
- *Mexico: 348241 (2017. 06. 01)
- *India: ID 0 048 290 (2017. 10. 23)
- *Chile: 57935 (2019. 08. 23)
Methods of enhancing HPV VLP purification
Registered Patents (* marked)
- *Rep. Korea: 10-1559622 (2015. 10. 05)
- *U.S.A.: 9994618 (2018. 06. 12)
- *Europe: 2881401 (2018. 04. 25)
- *Australia: 2013297306 (2017. 01. 12)
- *Canada: 2,880,420 (2018. 02. 27)
- *Japan: 6014763 (2016. 09. 30)
- *Indonesia: 180/KOLNP/2015 (2020. 10. 12)
- *China: ZL201380040425.9 (2018. 11. 06)
- *Brazil: BR 11 2015 002126 (2022. 10. 04)
- *Mexico: 361186 (2018. 11. 29)
- *India: ID 0 050 608 (2018. 04. 09)
- *Chile: 63.322 (2021. 10. 26)
